335 related articles for article (PubMed ID: 30810891)
1. Engineered and wild-type L. lactis promote anti-inflammatory cytokine signalling in inflammatory bowel disease patient's mucosa.
Simčič S; Berlec A; Stopinšek S; Štrukelj B; Orel R
World J Microbiol Biotechnol; 2019 Feb; 35(3):45. PubMed ID: 30810891
[TBL] [Abstract][Full Text] [Related]
2. Lactic Acid Bacteria with Concomitant IL-17, IL-23 and TNFα- Binding Ability for the Treatment of Inflammatory Bowel Disease.
Kosler S; Strukelj B; Berlec A
Curr Pharm Biotechnol; 2017; 18(4):318-326. PubMed ID: 28190384
[TBL] [Abstract][Full Text] [Related]
3. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10.
Steidler L; Hans W; Schotte L; Neirynck S; Obermeier F; Falk W; Fiers W; Remaut E
Science; 2000 Aug; 289(5483):1352-5. PubMed ID: 10958782
[TBL] [Abstract][Full Text] [Related]
4. Actobiotics as a novel method for cytokine delivery.
Steidler L; Rottiers P; Coulie B
Ann N Y Acad Sci; 2009 Dec; 1182():135-45. PubMed ID: 20074282
[TBL] [Abstract][Full Text] [Related]
5. Effects in the use of a genetically engineered strain of Lactococcus lactis delivering in situ IL-10 as a therapy to treat low-grade colon inflammation.
Martín R; Chain F; Miquel S; Natividad JM; Sokol H; Verdu EF; Langella P; Bermúdez-Humarán LG
Hum Vaccin Immunother; 2014; 10(6):1611-21. PubMed ID: 24732667
[TBL] [Abstract][Full Text] [Related]
6. In situ delivery of cytokines by genetically engineered Lactococcus lactis.
Steidler L
Antonie Van Leeuwenhoek; 2002 Aug; 82(1-4):323-31. PubMed ID: 12369199
[TBL] [Abstract][Full Text] [Related]
7. Germ therapy with IL-10 to treat inflammatory bowel diseases.
Michie C
Mol Med Today; 2000 Nov; 6(11):416. PubMed ID: 11074364
[No Abstract] [Full Text] [Related]
8. Targeting IL-6 by engineered Lactococcus lactis via surface-displayed affibody.
Zahirović A; Berlec A
Microb Cell Fact; 2022 Jul; 21(1):143. PubMed ID: 35842694
[TBL] [Abstract][Full Text] [Related]
9. Immunology. Therapeutic manipulation of gut flora.
Shanahan F
Science; 2000 Aug; 289(5483):1311-2. PubMed ID: 10979858
[TBL] [Abstract][Full Text] [Related]
10. Anticancer and Anti-Inflammatory Activity of Probiotic Lactococcus lactis NK34.
Han KJ; Lee NK; Park H; Paik HD
J Microbiol Biotechnol; 2015 Oct; 25(10):1697-701. PubMed ID: 26165315
[TBL] [Abstract][Full Text] [Related]
11. Lactococcus lactis carrying the pValac eukaryotic expression vector coding for IL-4 reduces chemically-induced intestinal inflammation by increasing the levels of IL-10-producing regulatory cells.
Souza BM; Preisser TM; Pereira VB; Zurita-Turk M; de Castro CP; da Cunha VP; de Oliveira RP; Gomes-Santos AC; de Faria AM; Machado DC; Chatel JM; Azevedo VA; Langella P; Miyoshi A
Microb Cell Fact; 2016 Aug; 15(1):150. PubMed ID: 27576902
[TBL] [Abstract][Full Text] [Related]
12. Lactococcus lactis subsp. cremoris FC alleviates symptoms of colitis induced by dextran sulfate sodium in mice.
Nishitani Y; Tanoue T; Yamada K; Ishida T; Yoshida M; Azuma T; Mizuno M
Int Immunopharmacol; 2009 Nov; 9(12):1444-51. PubMed ID: 19733697
[TBL] [Abstract][Full Text] [Related]
13. Secretion of biologically active pancreatitis-associated protein I (PAP) by genetically modified dairy Lactococcus lactis NZ9000 in the prevention of intestinal mucositis.
Carvalho RD; Breyner N; Menezes-Garcia Z; Rodrigues NM; Lemos L; Maioli TU; da Gloria Souza D; Carmona D; de Faria AM; Langella P; Chatel JM; Bermúdez-Humarán LG; Figueiredo HC; Azevedo V; de Azevedo MS
Microb Cell Fact; 2017 Feb; 16(1):27. PubMed ID: 28193209
[TBL] [Abstract][Full Text] [Related]
14. Dual engineered bacteria improve inflammatory bowel disease in mice.
Wu YQ; Zou ZP; Zhou Y; Ye BC
Appl Microbiol Biotechnol; 2024 May; 108(1):333. PubMed ID: 38739270
[TBL] [Abstract][Full Text] [Related]
15. Production of a particulate hepatitis C vaccine candidate by an engineered Lactococcus lactis strain.
Parlane NA; Grage K; Lee JW; Buddle BM; Denis M; Rehm BH
Appl Environ Microbiol; 2011 Dec; 77(24):8516-22. PubMed ID: 21984246
[TBL] [Abstract][Full Text] [Related]
16. Hsp65-Producing
Gusmao-Silva G; Aguiar SLF; Miranda MCG; Guimarães MA; Alves JL; Vieira AT; Cara DC; Miyoshi A; Azevedo VA; Oliveira RP; Faria AMC
Front Immunol; 2020; 11():562905. PubMed ID: 33072101
[TBL] [Abstract][Full Text] [Related]
17. Anti-inflammatory properties of fermented soy milk with Lactococcus lactis subsp. lactis S-SU2 in murine macrophage RAW264.7 cells and DSS-induced IBD model mice.
Kawahara M; Nemoto M; Nakata T; Kondo S; Takahashi H; Kimura B; Kuda T
Int Immunopharmacol; 2015 Jun; 26(2):295-303. PubMed ID: 25887264
[TBL] [Abstract][Full Text] [Related]
18. Probiotics alleviate inflammatory bowel disease in mice by regulating intestinal microorganisms-bile acid-NLRP3 inflammasome pathway.
Liu Z; Wang H
Acta Biochim Pol; 2021 Oct; 68(4):687-693. PubMed ID: 34648252
[TBL] [Abstract][Full Text] [Related]
19. Paracellular entry of interleukin-10 producing Lactococcus lactis in inflamed intestinal mucosa in mice.
Waeytens A; Ferdinande L; Neirynck S; Rottiers P; De Vos M; Steidler L; Cuvelier CA
Inflamm Bowel Dis; 2008 Apr; 14(4):471-9. PubMed ID: 18092343
[TBL] [Abstract][Full Text] [Related]
20. Cytokine production profile in intestinal mucosa of paediatric inflammatory bowel disease.
Vitale S; Strisciuglio C; Pisapia L; Miele E; Barba P; Vitale A; Cenni S; Bassi V; Maglio M; Del Pozzo G; Troncone R; Staiano A; Gianfrani C
PLoS One; 2017; 12(8):e0182313. PubMed ID: 28797042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
